inXitu XRD Combats Counterfeit Drugs

With a struggling economy, rising drug costs and an aging population using ever more prescription medicines, the need for inspection to differentiate counterfeit pharmaceuticals from authentic drugs has never been more important. Imitation drugs currently cost pharmaceutical companies an estimated $46 billion annually and carry a burden of liability and damaged reputations. Of greater concern, however, is the global risk to health and the rising deaths from ingested counterfeit medicines.

Recent advances in the field of X-ray diffraction now make it possible to introduce XRD analysis as a portable inspection tool for the purpose of phase identification and quantification of counterfeit pharmaceuticals.

Assisting various worldwide government agencies in their drive to combat the trafficking of fraudulent medications, inXitu is pleased to introduce a tailored version of its field portable XRD analyzer, TERRA. Completely contained and ready for operation in remote environments and at all points along the global pharmaceutical supply chain, Terra is well suited to the rapid determination of illegally manufactured medicines. In as little as two minutes Terra can perform qualitative and quantitative XRD analysis to validate pharmaceutical authenticity. An application report is available on request.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Evident Corporation (XRF / XRD). (2019, February 10). inXitu XRD Combats Counterfeit Drugs. AZoM. Retrieved on October 03, 2022 from

  • MLA

    Evident Corporation (XRF / XRD). "inXitu XRD Combats Counterfeit Drugs". AZoM. 03 October 2022. <>.

  • Chicago

    Evident Corporation (XRF / XRD). "inXitu XRD Combats Counterfeit Drugs". AZoM. (accessed October 03, 2022).

  • Harvard

    Evident Corporation (XRF / XRD). 2019. inXitu XRD Combats Counterfeit Drugs. AZoM, viewed 03 October 2022,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type